Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-Current Deffered Revenue (2022 - 2024)

Historic Non-Current Deffered Revenue for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q2 2024 value amounting to $222000.0.

  • NewAmsterdam Pharma's Non-Current Deffered Revenue rose 200393.11% to $222000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $222000.0, marking a year-over-year increase of 200393.11%. This contributed to the annual value of $1.0 million for FY2023, which is 7873.54% down from last year.
  • According to the latest figures from Q2 2024, NewAmsterdam Pharma's Non-Current Deffered Revenue is $222000.0, which was up 200393.11% from $444000.0 recorded in Q1 2024.
  • Over the past 5 years, NewAmsterdam Pharma's Non-Current Deffered Revenue peaked at $4.6 million during Q4 2022, and registered a low of $10551.7 during Q2 2023.
  • Its 3-year average for Non-Current Deffered Revenue is $1.3 million, with a median of $444000.0 in 2024.
  • In the last 5 years, NewAmsterdam Pharma's Non-Current Deffered Revenue tumbled by 7776.54% in 2023 and then surged by 200393.11% in 2024.
  • Over the past 3 years, NewAmsterdam Pharma's Non-Current Deffered Revenue (Quarter) stood at $4.6 million in 2022, then tumbled by 77.77% to $1.0 million in 2023, then tumbled by 78.21% to $222000.0 in 2024.
  • Its last three reported values are $222000.0 in Q2 2024, $444000.0 for Q1 2024, and $1.0 million during Q4 2023.